نتایج جستجو برای: radioimmunotherapy rit

تعداد نتایج: 1820  

Journal: :Cancer biotherapy & radiopharmaceuticals 2009
Frits Aarts Thijs Hendriks Annemarie Eek Wim J G Oyen Robert P Bleichrodt Otto C Boerman

In radioimmunotherapy (RIT), hematologic toxicity is the dose-limiting toxicity due to the long circulatory half-life of the antibody. Although intraperitoneal (i.p.) RIT results in high uptake of i.p. growing tumors, the radiolabeled antibody enters the circulation, resulting in bone marrow toxicity. Carbohydrate modification of antibodies could induce accelerated clearance of the antibody via...

Journal: :Nuclear medicine and biology 2014
Bérengère Piron Salomé Paillas Vincent Boudousq André Pèlegrin Caroline Bascoul-Mollevi Nicolas Chouin Isabelle Navarro-Teulon Jean-Pierre Pouget

INTRODUCTION Low dose-rate radioimmunotherapy (RIT) using (125)I-labelled monoclonal antibodies ((125)I-mAbs) is associated with unexpected high cytotoxicity per Gy. METHODS We investigated whether this hypersensitivity was due to lack of detection of DNA damage by the targeted cells. DNA damage was measured with the alkaline comet assay, gamma-H2AX foci and the micronucleus test in p53(-/-) ...

Journal: :Cancer medicine 2016
Rebecca Phaeton Zewei Jiang Ekaterina Revskaya Darrell R Fisher Gary L Goldberg Ekaterina Dadachova

Cervical cancer caused by the infection with the human papillomavirus (HPV) remains the fourth leading killer of women worldwide. Therefore, more efficacious treatments are needed. We are developing radioimmunotherapy (RIT) of HPV-positive cervical cancers by targeting E6 and E7 viral oncoproteins expressed by the cancer cells with the radiolabeled monoclonal antibodies (mAbs). To investigate t...

2013
Eric Frampas Caroline Rousseau Caroline Bodet-Milin Jacques Barbet Jean-Francois Chatal Françoise Kraeber-Bodéré

During the past two decades, considerable research has been devoted to radionuclide therapy using radiolabeled monoclonal antibodies and receptor binding agents. Conventional radioimmunotherapy (RIT) is now an established and important tool in the treatment of hematologic malignancies such as Non-Hodgkin lymphoma. For solid malignancies, the efficacy of RIT has not been as successful due to low...

Journal: :The oncologist 2009
Franck Morschhauser Martin Dreyling Ama Rohatiner Fredrick Hagemeister Angelika Bischof Delaloye

Non-Hodgkin's lymphoma (NHL) comprises both indolent forms, including follicular lymphoma (FL) and marginal zone lymphoma (MZL), and aggressive forms, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). FL and DLBCL are the most common subtypes of indolent and aggressive NHL, respectively. Although these lymphomas exhibit different clinical behaviors and outcomes, th...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2008
Diane E Milenic Kayhan Garmestani Erik D Brady Kwamena E Baidoo Paul S Albert Karen J Wong Joseph Flynn Martin W Brechbiel

PURPOSE Studies herein explore paclitaxel enhancement of the therapeutic efficacy of alpha-particle-targeted radiation therapy. EXPERIMENTAL DESIGN Athymic mice bearing 3 day i.p. LS-174T xenografts were treated with 300 or 600 microg paclitaxel at 24 h before, concurrently, or 24 h after [213Bi] or [212Pb]trastuzumab. RESULTS Paclitaxel (300 or 600 microg) followed 24 h later with [213Bi]t...

Journal: :Blood 2007
Anastasia Pantelias John M Pagel Nathan Hedin Laura Saganic Shani Wilbur Donald K Hamlin D Scott Wilbur Yukang Lin Diane Stone Don Axworthy Ajay K Gopal Oliver W Press

Pretargeted radioimmunotherapy (PRIT) using streptavidin (SA)-conjugated antibodies (Abs), followed by clearing agent and radiolabeled biotin is a promising method that can increase the effectiveness of RIT, while decreasing the toxicities associated with directly labeled Abs. Although CD20 has been the traditional target antigen for RIT of non-Hodgkin lymphoma (NHL), studies targeting HLA DR a...

2017
Murali Kesavan Jan Boucek William MacDonald Andrew McQuillan J. Harvey Turner

The purpose of this study was to evaluate prediction of prognosis after first-line radioimmunotherapy (RIT) of advanced follicular non-Hodgkin lymphoma (FL), by imaging with fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography (18F-FDG-PET/CT) three months after induction treatment by Iodine-131-rituximab (131I-rituximab). Objective response was determined using ...

2009
S. C. Srivastava L. F. Mausner R. C. Mease G. E. Meinken V. Joshi K. Kolsky M. Sweet Z. Steplewski

The potential of utilizing receptor-specific agents such as monoclonal antibodies (MAb), and MAb-derived smaller molecules, as carriers of radionuclides for the selective destruction of tumors has stimulated much research activity (Srivastava, 1988; Larson, 1994). The success of such applications depends on many factors, especially the tumor binding properties of the antibody reagent, the effic...

2012
Lubna Chaudhary Mehdi Hamadani

Follicular lymphoma (FL) is the second most common type of nonHodgkin lymphoma [1]. The development of rituximab represented a major breakthrough in the management of FL, with several landmark clinical trials consistently demonstrating superior survival outcomes with rituximab-containing chemoimmunotherapies compared to chemotherapy alone, both in the frontline [2-5] and relapsed/ refractory se...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید